Cancers 2022 September 1 [Link] Michel Adamina, Maxime Warlaumont, Martin D Berger, Silvio Däster, Raphaël Delaloye, Antonia Digklia, Beat Gloor, Ralph Fritsch, Dieter Koeberle, Thibaud Koessler, Kuno Lehmann, Phaedra Müller, Ralph Peterli, Frédéric Ris, Thomas Steffen, Christian Stefan Weisshaupt, Martin Hübner Abstract Peritoneal cancer (PC) is a dire finding, yet in selected patients, long-term survival…

Read More

International Journal of Molecular Science 2022 June 30 [Link] Claudia Baron, Marie Buchholz, Britta Majchrzak-Stiller, Ilka Peters, Daniel Fein, Thomas Müller, Waldemar Uhl, Philipp Höhn, Johanna Strotmann, Chris Braumann Abstract Malignant peritoneal mesothelioma is a rare tumor entity. Although cytoreductive surgery and hyperthermic intraperitoneal chemotherapy have increased overall survival, its prognosis remains poor. Established chemotherapeutics…

Read More

Langenbeck’s Archives of Surgery 2022 June 23 [Link] Miklos Acs, Michael Gerken, Ivana Gajic, Max Mayr, Jozef Zustin, Pompiliu Piso Abstract Purpose: This single-center study evaluated cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for diffuse malignant peritoneal mesothelioma (DMPM). Methods: Prospectively collected data from a single institution data registry was retrospectively investigated. Eighty-four…

Read More

Anticancer Research 2022 June [Link] Raphael Shamavonian, Ernest Cheng, Josh B Karpes, Shoma Barat, Nima Ahmadi, David L Morris Abstract Background/aim: The aim of the study was to determine outcomes and overall survival (OS) in patients undergoing cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for malignant peritoneal mesothelioma (MPM). Patients and methods: This was…

Read More

Canadian Journal of Surgery 2022 May 17 [Link] Rami Nassabein, Rami Younan, Rasmy Loungarath, Frederic Mercier, Francois Dagbert, Francine Aubin, Jean Pierre Ayoub, Mustapha Tehfé Abstract Background: Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) has recently shown promise for the treatment of patients with various types of peritoneal carcinomatosis (PC). However, it is…

Read More

Annals of Surgical Oncology 2022 March 14 [Link] Cristian D Valenzuela, Edward A Levine, Christopher W Mangieri, Rohin Gawdi, Omeed Moaven, Gregory Russell, Megan E Lundy, Kathleen C Perry, Konstantinos I Votanopoulos, Perry Shen Abstract Background: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) improves survival in abdominal cancer patients with metastatic disease limited to the…

Read More

Annals of Surgical Oncology 2021 October 28 [Link] Vahan Kepenekian, Julien Péron, Benoit You, Isabelle Bonnefoy, Laurent Villeneuve, Mohammad Alyami, Naoual Bakrin, Pascal Rousset, Nazim Benzerdjeb, Olivier Glehen Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is an aggressive primary peritoneal neoplasia. At diagnosis, few patients are eligible for a recommended cytoreductive surgery (CRS) and hyperthermic…

Read More

Frontiers in Oncology 2021 June 18 [Link] Louis Gros, Petr Szturz, Antonella Diciolla, Volker Kirchner, Solange Peters, Niklaus Schaefer, Martin Hubner, Antonia Digklia Abstract Mesothelioma is a malignancy of serosal membranes. Parietal pleura is the most common site, with peritoneum being the second most frequent location. Malignant peritoneal mesothelioma (MPM) is a rare and aggressive…

Read More

International Journal of Hyperthermia 2021 [Link] Parisa Malekzadeh, Meghan Good, Marybeth S Hughes Abstract Introduction: Malignant peritoneal mesothelioma (MPM) is a lethal cancer, with approximately 2% of diagnoses occurring in patients less than 40 years of age. The purpose of this study is to report the only long-term follow up and survival of pediatric patients…

Read More